A transdermal delivery system (TDS) for use in treatment of living bodies
may be applied as an open (liquid, gel) or closed (patch) article. The TDS
is composed of a particular active agent which dictates an associated
selection of certain solvents, solvent modifiers, solute modifiers and
skin stabilizers with which the medicament forms a true solution that
rapidly crosses the skin barrier. The associated selection of the
particular solvents, solvent modifiers, solute modifiers and skin
stabilizers is based on a balancing of the molecular properties of all the
components against the molecular properties of all the components plus the
particular active agent. The TDS may also include a source of cellular
energy to induce CAMP or cGMP. The TDS improves delivery of active agents
having a molecular weight greater than 340 Daltons and increases dosage
above 0.25 mg/day for such active agents.
